IBALGIN DUO EFFECT
50MG/G+2MG/G CRM 50G
| SÚKL code | 0207891 |
|---|---|
| Name of the product | IBALGIN DUO EFFECT |
| _MA_MEDICATION_DETAIL_INFO_MED_NAME i | IBALGIN DUO EFFECT |
| Supplement | 50MG/G+2MG/G CRM 50G |
| Strenght | 50MG/G+2MG/G |
| Pharmaceutical form | Cream |
| Package | 50G |
| Route | Cutaneous use |
| Language of the pack | Czech |
| Wrap type | Tube |
| Legal status | OTC medicinal products |
| Active substance |
IBUPROFEN (IBUPROFENUM) HEPARINOIDE S (HEPARINOIDUM S) |
| ATC group | M02AA13 |
| ATC group name | IBUPROFEN |
Marketing authorisation information
| Registration Number | 29/ 695/99-C |
|---|---|
| Type of MA | National |
| MA status | B - medicinal product after change, may be placed on the market for the period of 6 months (Placed on the market till) and used until expiration, not later than till the end of validity of the marketing authorisation (Valid till) |
| Placed on the market till | 31. 12. 2021 |
| MA Holder | sanofi-aventis, s.r.o., Praha |
| MA Holder country | ČESKÁ REPUBLIKA |
| Actual MA holder | Opella Healthcare Czech s.r.o., Praha |
| Actual MA holder country | ČESKÁ REPUBLIKA |
cz